Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

Rhea-AI Summary

Adicet Bio, Inc. (Nasdaq: ACET) is set to have its President and CEO, Chen Schor, participate in a fireside chat at the 2023 Guggenheim Oncology Conference on February 9, 2023, at 2:10 p.m. ET. This conference focuses on the development of allogeneic gamma delta T cell therapies for cancer, which are engineered to enhance tumor targeting and boost immune responses. Investors can access the live audio webcast on Adicet's website, with an archived replay available for 30 days post-event. For further details on Adicet's innovative therapies, visit Adicet Bio's website.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference being held from February 8-9, 2023.

Details of the event are as follows:
Date: Thursday, February 9, 2023
Time: 2:10 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005648/en/

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.

FAQ

What is the date and time of Adicet Bio's participation at the Guggenheim Oncology Conference?

Adicet Bio will participate in the Guggenheim Oncology Conference on February 9, 2023, at 2:10 p.m. ET.

Who is representing Adicet Bio at the 2023 Guggenheim Oncology Conference?

Chen Schor, President and CEO of Adicet Bio, will represent the company at the conference.

How can I access the webcast of Adicet Bio's presentation at the conference?

You can access the live audio webcast of Adicet Bio's presentation on their Investors section of the website.

What type of therapies is Adicet Bio developing?

Adicet Bio is developing allogeneic gamma delta T cell therapies for cancer.

Is there an archived replay of the Adicet Bio conference presentation?

Yes, an archived replay of the presentation will be available for 30 days after the event.